Ginger Vieira

Vermont

Author, Writer and Editor at Freelance

Author, freelancer & YouTuber! Living with type 1 diabetes since 1999. Find my books on Amazon and my videos on https://t.co/RiEvCHQBQB!

Featured in: Favicon

t1dexchange.org Favicon

salon.com

healthline.com Favicon

healthcentral.com Favicon

sevendaysvt.com Favicon

guardianlv.com Favicon

endocrineweb.com Favicon

beyondtype1.org Favicon

diabetesdaily.com Favicon

beyondtype2.org + 6 more

Articles

The Dream of "Smart" Insulin

Dec 14, 2024 | diabetesdaily.com | Ginger Vieira

Imagine this: an insulin that responds to blood sugar changes. An insulin that works when you need it and turns off when you don’t. Drugmakers have been working on a so-called “smart insulin” for decades. A smart insulin could allow people with diabetes to more aggressively target normal blood sugar levels. It could reduce the risk of both hypoglycemia and hyperglycemia, leading to better health outcomes in both the short and long term.
Muscle Loss and Type 2 Diabetes

Dec 2, 2024 | diabetesdaily.com | Ginger Vieira

If you live with type 2 diabetes, you may want to mind your muscles. Your muscles play a vital role in your metabolism. The muscles are the largest organ in the body, and they remove more sugar from your bloodstream than the rest of your organs combined. The health of the muscles significantly impacts the development and progression of diabetes. Unfortunately, many people with type 2 diabetes experience muscle atrophy (loss), which shares risk factors with diabetes itself.
A New Drug Could Prevent Nighttime Hypoglycemia

Nov 19, 2024 | diabetesdaily.com | Ginger Vieira

Imagine if there was a medication you could take every day that protected you from low blood sugar (hypoglycemia). A drug that only worked when you needed it. Zucara Therapeutics, a Toronto firm founded in 2014, is developing a drug that may protect adults living with type 1 diabetes from nighttime lows. Today, they are recruiting participants for their new clinical trial.
Should Everyone with Type 1 Diabetes Be Using a Closed-Loop Insulin Pump?

Nov 2, 2024 | diabetesdaily.com | Ginger Vieira

Automated insulin delivery (AID) systems, also known as closed loops, are changing the way we manage type 1 diabetes. These systems, which unite an insulin pump with a continuous glucose monitor (CGM), automatically select how much insulin you need, continually adjusting dosing throughout the day, based on how high or low your blood glucose gets. Some experts believe that almost everybody with type 1 diabetes should be using an AID system — and that they should all start as soon as they can.
Introducing the Eversense 365 CGM

Oct 31, 2024 | diabetesdaily.com | Ginger Vieira

The Eversense 365 Continuous Glucose Monitor (CGM) is the first of its kind: an implantable continuous glucose monitor that works for an entire year and is approved for use in people with type 1 and type 2 diabetes. Unlike competing CGMs, which stick to your skin for 14 days or less at a time, the Eversense sensor is surgically implanted under the skin, where it can stay for a year. Insertion only takes about 10 minutes.
Can This Triple-Combo Oral Therapy Restore Insulin Production?

Oct 24, 2024 | diabetesdaily.com | Ginger Vieira

A small biotechnology company in Israel says it can dramatically restore insulin production in people with type 1 diabetes by combining two existing medications with a proprietary version of a common supplement. Levicure’s triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. Here’s a look at Levicure’s history, research, and upcoming clinical trial.
Type 1 Cure Research Update: The Sernova Cell Pouch

Oct 5, 2024 | diabetesdaily.com | Ginger Vieira

Sernova is a biotechnology company focused on developing regenerative therapies to treat people with chronic diseases, including type 1 diabetes. The Sernova Cell Pouch System is a small, thin device that is filled with islet cells — the parts of the pancreas that produce beta cells and secrete insulin. The Cell Pouch, a new therapy under investigation, is surgically implanted just under the skin against the abdomen.
Dexcom Releases the First Over-the-Counter Continuous Glucose Monitor (CGM)

Sep 13, 2024 | diabetesdaily.com | Ginger Vieira

The Stelo continuous glucose monitor (CGM) is now for sale; it is the first over-the-counter CGM available in the United States. Made by Dexcom, Stelo aims to provide an affordable and accessible option for people with prediabetes and type 2 diabetes who don’t use insulin. Like other CGMs, the Stelo attaches to the skin and samples blood sugar levels around the clock, automatically sending the data to a smartphone.
Why Moms Are Less Likely to Pass on Type 1 Diabetes than Dads

Aug 23, 2024 | diabetesdaily.com | Ginger Vieira

A child is twice as likely to develop type 1 diabetes (T1D) if their father has the condition than if their mother does, according to a recent study presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain. Though both mothers and fathers can undoubtedly pass on genes that make type 1 diabetes more likely to develop, it appears that when women with T1D are pregnant, they also protect their growing babies from the condition.
Experts Release New Protocol for Managing Early Type 1 Diabetes

Aug 19, 2024 | diabetesdaily.com | Ginger Vieira

Medically reviewed by Anna Goldman, MD. Once upon a time, type 1 diabetes (T1D) wasn’t easily diagnosed until blood glucose levels were dangerously high with identifiable symptoms — like intense thirst, frequent urination, unexplained weight loss, insatiable hunger, and fatigue. Today, the earliest stages of T1D can be spotted with a simple blood test months or years before the need for daily insulin therapy.